Company profile: Jaguar Health
1.1 - Company Overview
Company description
- Provider of plant-based prescription medicines for urgent global health needs, including Crofelemer, an oral therapy for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, being studied for cancer therapy–related diarrhea and short bowel syndrome with intestinal failure; Canalevia-CA1 for chemotherapy-induced diarrhea in dogs; and NP-300, an investigational antisecretory for cholera-related diarrhea.
Products and services
- Crofelemer: A prescription-grade oral medication managing noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, also studied for cancer therapy–related diarrhea and short bowel syndrome
- Canalevia-CA1: A conditionally approved veterinary-grade treatment addressing chemotherapy-induced diarrhea in canine patients undergoing active chemotherapy regimens
- Crofelemer for Cancer Therapy–related Diarrhea: A Phase 3 clinical-stage trial of crofelemer preventing diarrhea in cancer patients receiving therapy regimens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Jaguar Health
Gritstone Bio
HQ: United States
Website
- Description: Provider of immunotherapies for cancer and infectious diseases, including GRANITE, a personalized neoantigen vaccine for solid tumors; SLATE, an off-the-shelf shared-neoantigen immunotherapy for KRAS-driven tumors; CORAL, prophylactic vaccines using self-amplifying mRNA; an HIV vaccine collaboration with Gilead; and EDGE, an AI platform to identify T cell targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gritstone Bio company profile →
Eiger BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, including lonafarnib, an oral farnesyl-transferase inhibitor blocking Hepatitis Delta Virus replication; avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism; Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eiger BioPharmaceuticals company profile →
BioVersys
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies and novel antibacterial products to combat multidrug-resistant bacterial infections, developing new mode-of-action compounds that switch off drug resistance and restore efficacy of approved antibiotics across Gram-negative, Gram-positive, and Tuberculosis pathogens, with a pipeline advancing through human clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVersys company profile →
SOM Biotech
HQ: Spain
Website
- Description: Provider of AI-based drug discovery and drug repurposing for orphan CNS diseases via the SOM AI PRO platform, validated by two successful Phase 2 trials (TTR amyloidosis; chorea in Huntington’s). Pipeline includes SOM3355 (oral VMAT2 inhibitor, Phase 2b), SOM0226 (TTR stabilizer, outlicensed), SOM1311 (PKU chaperone, expected to enter Phase 2a in 2024), and SOM0034 (DMD program, Phase 2 expected 2025).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SOM Biotech company profile →
Anadys Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for chronic hepatitis C, developing ANA598, a direct-acting antiviral (DAA), and resuming clinical development of ANA773.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anadys Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Jaguar Health
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Jaguar Health
2.2 - Growth funds investing in similar companies to Jaguar Health
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Jaguar Health
4.2 - Public trading comparable groups for Jaguar Health
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →